# US 2024/0189422 A1 · Combination cancer therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189422 A1
- Document ID: US20240189422A1
- Status: Published application
- Kind: A1
- Application number: 18/529,140
- Filed: 2023-12-05
- Published: 2024-06-13
- Earliest claimed: 2017-09-01
- Assignees: MicroVAX, LLC
- Applicants: MicroVAX, LLC
- Inventors: Albert B. Deisseroth; Nagy Habib
- Web page: https://patentgrep.com/patent/US20240189422A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 39/0011: {Cancer antigens}
- A61K 39/00117: {Mucins, e.g. MUC-1}
- A61K 39/39541: {against normal tissues, cells}
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/6031: {Proteins}
- C12N 2710/10043: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method and combination for treating a cancer patient by combining two distinct immuno-therapy solutions for administration to a patient within a common time period, comprising a checkpoint inhibitor antibody component such as a PD-1 or PD-L1 antibody administered by infusion, and a TAA/ecdCD40L vaccine component administered subcutaneously, wherein an initial antibody component administered is followed by at least several successive antibody boosts and an initial vaccine component administered is followed by at least several successive vaccine boosts, both the initial and boosts of each administered within at least said common time period, wherein the combined administration of said two distinct immuno-therapy solutions provides for an enhanced therapeutic effect, over that of the therapeutic effect of either of the two distinct immuno-therapy component solutions when administered alone as monotherapy.

## Claims

### Claim 1

A pharmaceutical immuno-oncology combination for use in treatment of cancer in an individual, said combination comprising:
(i) a checkpoint inhibitor, wherein the checkpoint inhibitor is an anti-PD-1 or an anti-PD-L1 inhibitory antibody; and,
(ii) an expression vector encoding a vaccine component (TAA/ecdCD40L), wherein the TAA/ecdCD40L is a fusion protein of Mucin-1 (MUC1, TAA) and the extracellular domain of a CD40 ligand (ecd), wherein the ecd excludes at least the transmembrane domain that inhibits secretion;
wherein:
(a) the checkpoint inhibitor and the vaccine component are both to be administered to the individual including additional boosts of the same;
(b) the administration generates an immune response against cancerous antigen in an individual by effecting a reduction of a total population of CD11b positive cells in the cancerous tumor and increases the magnitude of the antitumor immune response in the individual; and
(c) the checkpoint inhibitor and the vaccine components are administered as a combination at effective amounts over a common time period to produce through their biological interaction an enhanced synergistic immune response greater than an immune response by the checkpoint inhibitor administered as a monotherapy.

### Claim 2 (depends on 1)

A pharmaceutical immuno-oncology combination for use according to claim 1, wherein said components as a combination have the capacity to induce a statistically significant decrease in said CD11b positive cells inducing a change in the tumor micro-environment and increase CD8 T cells thereby suppressing tumor growth by a two-fold factor.

### Claim 3 (depends on 1)

A pharmaceutical immuno-oncology combination for use according to claim 1, wherein said vaccine component comprises a replication incompetent antigen specific adenoviral vector Ad-sig-hMUC-1/ecdCD40L, said vector comprising a transcription unit containing a secretory signal sequence (“sig”) and the TAA/ecdCD40L fusion protein sequence, wherein the mucin antigen fragment TAA is from human mucin-1 antigen (“hMUC-1”), administered subcutaneously.

### Claim 4 (depends on 1)

A pharmaceutical immuno-oncology combination according to claim 1, wherein the checkpoint inhibitor effective amount is in the range of 20 mg to 250 mg.

### Claim 5 (depends on 1)

A pharmaceutical immuno-oncology combination for use according to claim 1, wherein said checkpoint inhibitor effective amount is in the range of 2-12 mg per kg of weight of an individual.

### Claim 6 (depends on 1)

A pharmaceutical immuno-oncology combination for use according to claim 1, wherein the effective amount for the vaccine component is in the range of 0.1 VPU to 1.0×1011 VPU.

### Claim 7

A pharmaceutical combination for treating cancerous tumor tissue, comprising at least two immuno-therapeutic components adapted for administration to a patient over a common time period for generating a biological interaction between the two components to provide for a synergistic increased immune response, the immuno-therapeutic combination comprising:
an antigen non-specific PD-1 or PD-L1 antibody therapy component active for the cancer type to be treated and adapted to be administered to the patient including additional boosts of the antibody therapy component, and
a MUC-1/ecdCD40L antigen specific vaccine therapy component adapted to be administered to the patient including additional boosts of the MUC-1/ecdCD40L antigen specific vaccine therapy component,
wherein said two components are administered as a combination immunotherapy, to reduce a statistically significant percentage of a total of CD11b positive cells present in the cancerous tumor tissue and generate an immune response to (i) induce a prolongation of survival in the patient, and (ii) induce an influx in MUC-1 antigen specific CD8 T cells that traffick into the cancerous tumor tissue, enabling an overall synergistic increase in the patient's immune response to suppress tumor growth by more than the combined effects seen when each of the vaccine therapy component and antibody therapy component is given alone as monotherapy.

### Claim 8 (depends on 7)

A pharmaceutical combination according to claim 7, wherein said influx of MUC-1 antigen specific CD8 T cells into the tumor tissue induce a significant prolongation of survival in the patient.

### Claim 9 (depends on 7)

A pharmaceutical combination according to claim 7, wherein an effective therapeutic amount for the vaccine therapy component ranges from approximately 0.1×1011 vector particles to 1.0×1011 vector particles and an effective therapeutic amount of said antibody therapy component ranges from 2-12 milligrams per kilogram weight of the individual.

### Claim 10 (depends on 7)

A pharmaceutical combination according to claim 7, wherein said antibody therapy component is for administration by infusion and said MUC-1/ecdCD40L antigen specific vaccine therapy component is an expression vector Ad-sig-hMUC-1/ecdCD40L for subcutaneous administration.

### Claim 11

A pharmaceutical combination for treating a patient having cancerous tumor tissue, for inducing an immune response in the cancerous tumor tissue, comprising:
an antigen specific single vector vaccine component Ad-sig-hMUC-1/ecdCD40L at a first effective amount to generate an immune response in antigen specific cancerous tumor tissue, and
an antigen non-specific PD-1 or PD-L1 antibody component at a second effective amount to generate an immune response in the cancerous tumor tissue,
wherein the vector vaccine component and the antibody component comprise an immuno-therapeutic combination as administered to the patient during a common time period and are adapted to biologically interact causing a significant reduction of a total population of CD11b positive cells in the tumor tissue, inducing both an increase in patient survival time and an increase in the magnitude of the anti-tumor immune response resulting in a tumor suppression effect more than the effect of said two components each acting alone as monotherapy in suppression of the patient's tumor growth in the cancerous tumor tissue.

### Claim 12 (depends on 11)

A pharmaceutical combination according to claim 11, wherein said vector vaccine and antibody components as a combination have the capacity to synergistically induce an increase in a patient's MUC-1 specific CD8 effector T cells, thereby increasing a population of patients responding to the component combination of therapy over a population of patients responding to each of said components as monotherapy.

### Claim 13 (depends on 11)

A pharmaceutical combination according to claim 11, wherein during said common period a minimum of both five vaccine components are administered and ten antibody components are administered.

### Claim 14 (depends on 11)

A pharmaceutical combination according to claim 11, wherein said CD11b positive cells reduction correlates with an increase in a PD-1 patient population response rate.

### Claim 15 (depends on 11)

A pharmaceutical combination according to claim 11, wherein the vaccine component and the antibody component as a combination convert at least a portion of the immunoregulatory environment at a site of the cancerous tumor in a patient from immunoinhibitory to immunostimulatory, and said immune response includes an ability to fully suppress antigen specific cancerous tumor tissue growth for at least 20 percent of the patients.

### Claim 16

A method for treating a patient having cancerous tumor tissue, for inducing an immune response in the cancerous tumor tissue, comprising:
administering an antigen specific single vector vaccine component Ad-sig-hMUC-1/ecdCD40L at a first effective amount to generate an immune response in antigen specific cancerous tumor tissue, and
administering an antigen non-specific PD-1 or PD-L1 antibody component at a second effective amount to generate an immune response in the cancerous tumor tissue,
wherein the vector vaccine component and the antibody component, as an combination when administered to the patient during a common time period are adapted to biologically interact causing a significant reduction of a total population of CD11b positive cells in the cancerous tumor tissue, inducing both an increase in patient survival time and an increase in the magnitude of the anti-tumor immune response resulting in a tumor suppression effect more than the effect of said two components each acting alone as monotherapy in suppression of the patient's tumor growth in the cancerous tumor tissue.
